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Introduction and objectives
NOMID, also known as CINCA syndrome, is a domi-
nantly inherited autoinflammatory disease caused by
NLRP3 mutations. The pathophysiology of NOMID is
explained by gain of function mutation of NLRP3,
which activates NLRP3 inflammasome and produce an
excess of IL-1b. This mechanism is supported by clinical
observation that anti-IL-1 therapy is effective on its sys-
temic inflammation. However, one of its characteristic
features, epiphyseal overgrowth, is considered to be
resistant to anti-IL-1 therapy, which raises a question
that other mechanism than NLRP3 inflammasome may
play a role in the epiphyseal overgrowth. In this study,
we investigated the effect of mutated NLRP3 on chon-
drocytes using induced pluripotent stem cells (iPSCs)
derived from NOMID patients, and tried to identify
drugs to treat the abnormal chondrocytes overgrowth.
Methods
We established isogenic iPSCs with wild-type or mutant
NLRP3 from 2 NOMID patients with NLRP3 somatic
mosaicism. We differentiated the iPSCs into chondro-
cytes, and the phenotypes of chondrocytes derived from
iPSCs with wild-type NLRP3 and mutant ones were
compared, particularly the size of the chondrocyte tissue
produced.
Results
Mutant iPSCs produced larger chondrocyte masses than
wild-type iPSCs owing to glycosaminoglycan overpro-
duction. We also observed increased expression of
SOX9, which is a chondrocyte master-regulator, on chon-
drocyte masses derived from mutant iPSCs. In addition, in
vivo transplantation of mutant cartilaginous pellets into
immunodeficient mice NOG caused disorganized endo-
chondral ossification. Enhanced chondrogenesis observed
in chondrocyte masses derived from mutant iPSCs was
independent of caspase-1 and IL-1, and thus probably the
NLRP3 inflammasome. Reporter assays using the human
SOX9 promoter in chondroprogenitor cells revealed that
the proximal CREB/ATF-binding site was critical for
SOX9 overexpression caused by mutated NLRP3. These
data was correlated with increased levels of cAMP and
phosphorylated CREB in mutant chondroprogenitor cells.
We are now developing high throughput screening system
to identify compounds to inhibit the abnormal chondro-
cytes overgrowth.
Conclusion
Our findings indicate that the intrinsic hyperplastic
capacity of NOMID chondrocytes is dependent on the
cAMP/PKA/CREB pathway, independent of the NLRP3
inflammasome.
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